Skip to main content
Premium Trial:

Request an Annual Quote

NEWSBRIEF: Variagenics Licenses Gene Patent Rights to Third Wave

SAN FRANCISCO, May 9 - Variagenics licensed its cardiovascular patent rights to its methylenetetrahydrofolate reductase gene to Third Wave Technologies, the companies announced today.


The deal grants Third Wave worldwide non-exclusive rights to commercialize reagents and molecular diagnostic tests for the assessment of thrombo-embolic disease risk, according to Variagenics.


Variagenics retains the rights to develop applications in oncology and other disease areas.


Financial terms of the agreement were not disclosed.


The MTHFR polymorphism influences the activity of the MTHFR protein and may affect susceptibility to a number of diseases and influence response to drugs, according to Variagenics. 


"We view this relationship with Third Wave as an important step in our transition to a product-focused molecular diagnostics business model," Joseph Mohr, president of Variagenics, said in a statement.

The Scan

Foxtail Millet Pangenome, Graph-Based Reference Genome

Researchers in Nature Genetics described their generation of a foxtail millet pangenome, which they say can help in crop trait improvement.

Protein Length Distribution Consistent Across Species

An analysis in Genome Biology compares the lengths of proteins across more than 2,300 species, finding similar length distributions.

Novel Genetic Loci Linked to Insulin Resistance in New Study

A team reports in Nature Genetics that it used glucose challenge test data to home in on candidate genes involved in GLUT4 expression or trafficking.

RNA Editing in Octopuses Seems to Help Acclimation to Shifts in Water Temperature

A paper in Cell reports that octopuses use RNA editing to help them adjust to different water temperatures.